Skip to content

optimization study of emergent PCI surgery in acute STEMI patients

optimization study of emergent PCI surgery in acute STEMI patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003120
Enrollment
Unknown
Registered
2013-03-12
Start date
2012-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute st-elevation myocardial infarction

Interventions

single-vessel disease group:Stent implantation
multi-vessel disease group:non-infarct-related artery emergent PCI
Intensive statin group:non-infarct-related artery emergent PCI

Sponsors

Capital medical university affiliated Beijing Anzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: acute STEMI patients, that is, ischemic chest pain continued for more than 30min, buccal dissolving nitroglycerin is ineffective; adjacent two or more lead ST-segment elevated, limb lead >=0.1mV, chest lead >=0.2mV; onset within 12h; male or non-pregnant women above 18 years old (including 18-year-old) and under 80 years old; informed consent form approved by the Ethics Committee must be signed.

Exclusion criteria

Exclusion criteria: Exclusion criteria: complicated by cardiogenic shock; complicated by severe valvular heart disease; complicated by myocardial disease; IRA of stent thrombosis; patients with coronary bypass grafting; patients accepting heart transplant; bleeding tendency, active peptic ulcer, medical history of hemorrhagic apoplexy, medical history of cerebral arterial thrombosis within six months as well as antiplatelet and anticoagulant therapy contraindications that can not be effective anticoagulant; patients with multiple organ failure; patients with advanced tumors; allergic to contrast agent; patients can not adhere to the study protocol, such as can't be followed-up or can not complete this study.

Design outcomes

Primary

MeasureTime frame
Cardiac death;Nonfatal myocardial infarction;target lesion revascularization;Persistent angina;strok;

Secondary

MeasureTime frame
Liver and kidney function damage;Severe bleeding;Elevated levels of creatine kinas;

Countries

China

Contacts

Public ContactShuzheng Lv
shuzheng@medmail.com.cn+86 13911065536

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026